Weill Cornell Medicine Experts Presenting at 2021 ASCO GU

San Francisco, CA (UroToday.com) -- Poster session begins Thursday, February 11 at 8:00AM ET


Prostate Cancer - Advanced Disease Poster Session:


Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. (Abstract 48)
PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide. (Abstract 84)

Advanced Prostate Cancer Trials in Progress Poster Session:

A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). (Abstract TPS188)

Urothelial Carcinoma Poster Session:

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. (Abstract 438)
NOTE - This presentation is also featured in the urothelial carcinoma clinical trials poster highlights session on Friday, February 12 at 8:00 AM ET.

Cora N. Sternberg, M.D. Clinical Director of the Englander Institute of Precision Medicine at Weill Cornell Medicine and NewYork-Presbyterian
Dr. Sternberg’s areas of expertise:
  • Bladder cancer
  • Genomics
  • Immunotherapy
  • Kidney cancer
  • Prostate cancer
  • Testicular cancer
  • Urologic cancer
  • Urothelial cancer

Prostate Cancer - Advanced Disease Poster Session:

The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer (Abstract 41)
Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study (Abstract 46)

Advanced Prostate Cancer Trials in Progress Poster Session:

A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). (Abstract TPS188)

Scott T. Tagawa, MD, MS, FACP, Medical Director of the Genitourinary Oncology Research Program at Weill Cornell Medicine and NewYork-Presbyterian
Dr. Tagawa’s areas of expertise:
  • Bladder Cancer
  • Immunotherapy
  • Kidney Cancer
  • Medical Oncology
  • Prostate Cancer
  • Testicular Cancer
  • Thrombosis
  • Urologic Cancer

Urothelial Carcinoma Poster Session:

Single-cell DNA targeted sequencing (scDNA-seq) to test therapeutic vulnerabilities in urothelial cancer (UC) patient-derived organoids (PDO). (Abstract 464)

Bishoy M. Faltas, MD, Genitourinary Oncologist at Weill Cornell Medicine and NewYork-Presbyterian, Director of Bladder Cancer Research, Englander Institute for Precision Medicine
Dr. Faltas’ areas of expertise:
  • Bladder Cancer
  • Cancer of Ureter
  • Genomics
  • Immunotherapy
  • Kidney Cancer
  • Prostate Cancer
  • Urethral Cancer
Source: American Society of Clinical Oncology Genitourinary Cancer Symposium. (2021, February 10). Weill Cornell Medicine Experts Presenting at 2021 ASCO GU [Press release]. Retrieved from ASCO Meeting Library ASCO GU 2021

Related Content:
The PROSPER Trial: Enzalutamide Demonstrates Significant Improvement in Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer - Cora Sternberg
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
email news signup